COMP <GO>
SRRK vs CRSP // RETURN ON INVESTED CAPITAL (ROIC)
Scholar Rock Holding Corporation (NASDAQ) VS. CRISPR Therapeutics AG (NASDAQ) • 15-METRIC TALLY: SRRK 5
— CRSP 4
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: CRSP
LAST: $44.18 (+2.15%) • MKT CAP: $5.38B
roic
-35.00%
LAST: $54.26 (+0.28%) • MKT CAP: $5.25B
roic
-30.60%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SRRK VS. CRSP)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SRRK | CRSP | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | — | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | -35.00% | -30.60% | -4.40 | CRSP | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -5.59% | -6.59% | +1.00 | SRRK | /fcf-yield <GO> |
| Operating Margin | — | -60.00% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | -60.00% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) | 7.70% | -65.00% | +72.70 | SRRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 13.67 | 7.97 | +5.70 | SRRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 4/9 | +1.00 | SRRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 50.5 | 54.9 | -4.40 | CRSP | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 1.02 | 1.12 | -0.10 | CRSP | /macro-sensitivity <GO> |
| Forward P/E Multiple | 32.0x | 28.0x | +4.00 | CRSP | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $5.38B | $5.25B | $133.9M | SRRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SRRK REV | CRSP REV | SRRK GROSS % | CRSP GROSS % | SRRK FCF | CRSP FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $0 | $3.5M | — | — | -$300.6M | -$345.9M |
| FY 2024 | $0 | $37.3M | — | — | -$201.0M | -$144.7M |
| FY 2023 | $0 | $371.2M | — | — | -$145.2M | -$277.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SRRK // BETA 1.02
CRSP // BETA 1.12